Press Releases

WASHINGTON, DC, February 2, 2017—To address the underrepresentation of African Americans and Latinos in all aspects of neurological research, UsAgainstAlzheimer’s has launched a multi-pronged engagement strategy to build a national network of diverse researchers, patients, caregivers and stakeholder groups for collaboration and knowledge sharing around barriers, facilitators and priorities in Alzheimer’s research. The project aims to foster effective and inclusive community engagement and collaboration strategies.

WASHINGTON, DC—Dementia Friendly America (DFA), a national collaborative representing the nation’s leading Alzheimer’s organizations, companies and advocates, recently announced the U.S. launch of the Dementia Friends program, a global initiative that aims to empower and educate individuals about dementia. UsAgainstAlzheimer’s, a funding partner of DFA, is pleased to be a fervent initiator and supporter of this effort to serve the millions of people and their caregivers affected by Alzheimer’s disease.

Open Letter from UsAgainstAlzheimer’s Co-Founder and Chairman Specifies Initial Next Steps to Achieve Critical Advancements Toward Effective Treatments and a Cure

WASHINGTON, DC—In a letter released today by UsAgainstAlzheimer’s, Co-Founder and Chairman George Vradenburg said the negative clinical trial of a once-promising Alzheimer’s drug, Solanezumab, which showed clinically insignificant ability to slow cognitive decline in Alzheimer’s patients, should be viewed not as a failure, but as a development that “provides valuable lessons and suggests a way forward in the fight against Alzheimer’s.”

WASHINGTON, DC—Following the passing of the 21st Century Cures Act by the U.S. Senate on Wednesday, UsAgainstAlzheimer’s applauds the bipartisan action by Congress to hasten and strengthen the nation’s abilities to develop, test and deliver game-changing therapies for diseases and illnesses that cripple families.

WASHINGTON, DC—Following today’s announcement that Eli Lilly’s drug that would slow memory loss in people with mild cases of Alzheimer’s disease failed Phase III clinical trials, UsAgainstAlzheimer’s emphasizes that while this news is a setback for the millions of people around the world with dementia, the pipeline could see more successful results in the near future.

Pages

^ Back to Top